2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
David S. Hong, MD, discusses the primary objective of the ongoing phase 1/2 CodeBreaK 101 trial in mutated advanced colorectal cancer and other solid tumors harboring KRAS G12C mutations.
David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the primary objective of the ongoing phase 1/2 CodeBreaK 101 trial (NCT04185883) in mutated advanced colorectal cancer (CRC) and other solid tumors harboring KRAS G12C mutations.
Similar to other phase 1 trials, CodeBreaK 101 is expanding into respective tumor types such as advanced CRC, Hong says. The primary objective of the study remains to identify a recommended phase 2 dose of sotorasib (Lumakras), plus dose-limiting toxicities, Hong explains.
Though CodeBreaK 101 is not a randomized trial, investigators are observing efficacy signals, such as overall response, duration of response, and progression free survival, Hong concludes.